Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda
ReutersMar 6, 2025 12:50 PM
March 6 (Reuters) - Plus Therapeutics PSTV.O:
PLUS THERAPEUTICS GRANTED U.S. FDA ORPHAN DRUG DESIGNATION FOR RHENIUM (186RE) OBISBEMEDA FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES IN PATIENTS WITH LUNG CANCER
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilizeTradingKey
5 hours ago
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%TradingKey
Tue, Sep 9
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.TradingKey
Mon, Sep 8
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
Tradingkey
